Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) shares crossed below its fifty day moving average during trading on Thursday. The stock has a fifty day moving average of $0.99 and traded as low as $0.95. Werewolf Therapeutics shares last traded at $0.9857, with a volume of 560,895 shares trading hands.
Analyst Upgrades and Downgrades
A number of brokerages have recently commented on HOWL. Wall Street Zen upgraded Werewolf Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 22nd. Weiss Ratings raised shares of Werewolf Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Thursday, September 10th. Finally, Zacks Research downgraded shares of Werewolf Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Tuesday, November 3rd. One research analyst has rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Werewolf Therapeutics currently has a consensus rating of "Hold" and an average price target of $2.50.
Read Our Latest Research Report on Werewolf Therapeutics
Werewolf Therapeutics Trading Down 4.3%
The firm has a market cap of $47.91 million, a price-to-earnings ratio of -1.64 and a beta of 0.55. The firm's 50 day simple moving average is $0.99 and its two-hundred day simple moving average is $0.71.
Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) last released its earnings results on Friday, November 13th. The company reported ($0.20) earnings per share for the quarter, beating analysts' consensus estimates of ($0.22) by $0.02. As a group, equities research analysts anticipate that Werewolf Therapeutics, Inc. will post -0.89 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Werewolf Therapeutics
A number of hedge funds have recently made changes to their positions in the stock. Vilga Financial Planning LLC bought a new stake in Werewolf Therapeutics during the 3rd quarter worth $49,000. StoneX Group Inc. increased its position in shares of Werewolf Therapeutics by 174.3% during the third quarter. StoneX Group Inc. now owns 54,856 shares of the company's stock worth $51,000 after buying an additional 34,856 shares during the period. Vontobel Holding Ltd. bought a new position in shares of Werewolf Therapeutics in the 3rd quarter worth about $55,000. Virtu Financial LLC increased its holdings in Werewolf Therapeutics by 99.6% in the third quarter. Virtu Financial LLC now owns 90,749 shares of the company's stock worth $84,000 after purchasing an additional 45,282 shares in the last quarter. Finally, BlackRock Inc. acquired a new position in shares of Werewolf Therapeutics during the 2nd quarter valued at $37,000. 64.84% of the stock is currently owned by institutional investors and hedge funds.
Werewolf Therapeutics Company Profile
(
Get Free Report)
Werewolf Therapeutics, Inc. is a clinical-stage biotechnology company developing medicines for cancer. Its research focuses on cytokines, immune-signaling proteins that can stimulate the body's immune response against tumors. The company's INDUKINE platform is designed to keep cytokine therapies inactive until they reach the tumor environment, with the goal of limiting effects on healthy tissue. Its investigational programs include WTX-124, based on interleukin-2, and WTX-330, based on interleukin-12.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Werewolf Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Werewolf Therapeutics wasn't on the list.
While Werewolf Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.